Prosecution Insights
Last updated: November 04, 2026
Application No. 18/454,411

SLEEP PATTERN BREATHING DETECTION

Non-Final OA §103
Filed
Aug 23, 2023
Priority
Aug 23, 2022 — provisional 63/373,266 +3 more
Examiner
ORTEGA, MARTIN NATHAN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Neurostim Technologies LLC
OA Round
3 (Non-Final)
27%
Grant Probability
At Risk
3-4
OA Rounds
9m
Est. Remaining
60%
With Interview

Examiner Intelligence

Grants only 27% of cases
27%
Career Allowance Rate
22 granted / 82 resolved
-43.2% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
40 currently pending
Career history
125
Total Applications
across all art units

Statute-Specific Performance

§101
16.6%
-23.4% vs TC avg
§103
41.1%
+1.1% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
28.7%
-11.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 82 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/11/2026 has been entered. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-4, 9, 10-13, and 18-19 are rejected under 35 U.S.C. 103 as being unpatentable over Toong et al. (US 20210001122- Previously cited), hereinafter Toong, and further in view of Ma et al. (Combined unsupervised-supervised machine learning for phenotyping complex diseases with its application to obstructive sleep apnea -2021), hereinafter Ma. Regarding claims 1, 10, and 19, Toong teaches a system, method, and non-transitory computer readable medium having instructions, comprising detecting an treating an occurrence of an apnea event during a sleep period of a user (see abstract), the system and method comprising: affixing a patch externally on a dermis of the user, the patch comprising a flexible substrate, an adhesive on a first side adapted to adhere to the dermis of the user, a processor directly coupled to the substrate, and one or more sensors directly coupled to the substrate; receiving biometric data corresponding to the user (¶ [0279], “The audio sensing device detects the sounds of snoring”); determining an SpO2 level of the user using the one or more sensors (¶[0277-9,0312], “The oximeter monitors the saturation of peripheral oxygen (SpO2)”); based at least on the determined SpO2 level, detecting the apnea event (¶0277,0279], “respiration monitoring device 3020 measures other biometric attributes of the user 3100 to determine the beginning of an apnea episode”); in response to the detecting, treating the apnea event (¶ [0246,0276], “the patch is used to detect and then reduce/treat the number of apnea or hypopnea episodes during sleep”), and in response to detecting and based on the biometric data and the determined SpO2 level, using a trained machine learning to predict sleep apnea severity and associated conditions, wherein the trained model includes population data and tuned for the user using data from sleep periods of the user (¶[0294], “OSA suppression and detection systems 3000 use AI techniques such as correlation analysis to correlate real-time data recordings of the user with larger population databases to produce comparative or predictive analyses. In some examples, machine-learning algorithms are employed to build up the user's sleep history and provide specific predictors of sleep apnea severity and associated conditions” (emphasis added)) Toong fails to explicitly teach in response to the detecting and based on the biometric data and the determining SpO2 level, using a trained machine learning model to predict a probabilistic onset of one or more comorbidities of the user, wherein the trained machine learning model is trained using population polysomnography data including marked apnea events and corresponding SpO2 monitoring data and is tuned for the user using data from sleep periods of the user. Ma teaches a combined unsupervised-supervised machine learning for phenotyping key features that show comorbidity development for OSA-related cardio-neuro-metabolic diseases (abstract). The data input into the model is based on PSG data (abstract). 18 features, including number of apnea events and oxygen saturation, account for 95% of the total importance in predicting comorbidity outcomes (Fig. 4 and pg. 5, “Among 43 PSG features, 18 features accounted for 95% of the total importance in predicting comorbidity outcomes”). The trained model is then used to predict a probability of one or more comorbidities (pg. 5 and 9-10). It would have been obvious to one of ordinary skill in the art at the time the invention was effectively filed to have modified the method of Toong, to use a trained machine learning model to predict a probabilistic onset of one or more comorbidities of the user and where the model is trained using population polysomnography data including marked apnea events and corresponding SpO2 monitoring data, as taught by Ma, to include important elements in the diagnosis OSA patients for better prognosis of associated comorbidities (pg. 2 of Ma). Regarding claims 2 and 11, Toong teaches treating comprising using an external hypoglossal nerve stimulator (¶ [0163,0247], “The TNSS creates an action potential through an externally applied electric field from outside the body” and “stimulating the hypoglossal nerve to relieve apnea to provide a closed-loop system”). Regarding claims 3 and 12, Toong teaches treating comprising using an internal hypoglossal nerve stimulator system (¶ [0165,0247], “electric fields capable of causing action potentials can be generated by electronic stimulators connected to electrodes that are implanted surgically . . . . Such devices may be used instead of implants and/or with implants”, and “stimulating the hypoglossal nerve to relieve apnea to provide a closed-loop system”). Regarding claims 4 and 13, Toong teaches treating comprising using a positive airway pressure device (¶ [0336], “Use of OSA system 3000 avoids awakening the user to administer CPAP to observe the effects of treatment”). Regarding claims 9 and 18, Tong teaches the patch in wireless communication with a smart device (¶ [0064,0073], the patch communicates with a smart phone). Regarding claims 5, 14 and 20, Toong fails to teach the using the trained machine learning model comprising training the machine learning model using input PSG recordings. Ma teaches using all PSG data is important in diagnosing OSA patients, thus better prognosis of associated comorbidities (pg. 2), It would have been obvious to one of ordinary skill in the art at the time the invention was effectively filed to have modified the method of Toong, to use a trained machine learning model to predict a probabilistic onset of one or more comorbidities of the user and where the model is trained using population polysomnography data including marked apnea events and corresponding SpO2 monitoring data, as taught by Ma, to aid in diagnosing OSA patients for better prognosis of associated comorbidities (pg. 2 of Ma). Claims 6, 15, and 21 are rejected under 35 U.S.C. 103 as being unpatentable over Toong in view of Ma, as applied to claim 1, and further in view of Apte et al. (US 20120286520- Previously cited), hereinafter Apte. Regarding claims 6, 15, and 21, Toong fail to teach wherein the biometric data comprises at least one of obesity, restless leg syndrome, periodic leg movement disorder, or bruxism. However, Ma does teach that one of the PSG features obtained includes periodic leg movement, but still distinct from the disorder (Table 1 of Ma). Apte teaches a system for characterizing one or more sleep related conditions and determining one or more therapies based on the characterization (abstract). The system is configured to perform cross-condition analyses for a plurality of sleep related conditions, e.g., determining comorbidities (¶[0019]). The sleep related conditions that are obtained include apnea, bruxism, restless legs syndrome, etc. (¶[0022]). Therefore, Apte’s system requires obtaining biometrics to determine comorbidities which are then used to provide therapy (¶[0016]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was effectively filed to have modified the device of Toong-Ma, such that biometric data comprises at least one of obesity, restless leg syndrome, periodic leg movement disorder, or bruxism, as taught by Apte, to aid in characterizing one or more sleep related conditions and providing therapy based on the characterization. Claims 8, 17, and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Toong in view of Ma, as applied to claim 1, and further in view of Danilov et al. (US 8849407- Previously cited), hereinafter Danilov. Regarding claims 8, 17, and 22, Toong-Ma fail to teach wherein the patch comprises a first portion adapted to be placed on a bridge of a nose of the user and at least one second portion adapted to be placed on a cheek of the user. Danilov teaches an electrode patch in the form of a mask or single patch that comprises a plurality of portions (figs. 1-3, mask 12). The mask/patch comprise a plurality of electrodes that cover all of the nose and cheeks to aid in monitoring the user’s conditions without the need for intrusive measures or other burdensome or painful procedures (col. 2-3 and 4, ln. [65-67;1-11;14-25]). Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was effectively filed to have modified the device of Toong-Ma, such that wherein the patch comprises a first portion adapted to be placed on a bridge of a nose of the user and at least one second portion adapted to be placed on a cheek of the user, at taught by Danilov, to aid in monitoring the user’s conditions without the need for intrusive measures or other burdensome or painful procedures. Response to Arguments Applicant's arguments filed 08/12/2026 have been fully considered but they are not fully persuasive. Applicant’s arguments with respect to amended independent claims have been considered but are moot because amendments require new grounds of rejection in view of Ma. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kahlert et al. a sensor arrangement for detecting physiological parameters of a subject, a detection system for detecting a sleeping position of the subject and an alert system for instructing a change in sleep position of the subject. From the monitored physiological parameters, fluid accumulation is identified in a region of the body of the subject. The alert system is controlled to instruct a change in sleep position thereby to reverse the fluid accumulation. US 20220203063 Shelly et al. a method for assisting a patient in avoiding obstructive sleep apnea (OSA) or for weaning from a PAP therapy includes: receiving in a controller health related data of the patient obtained from the patient by one or more electronic devices associated with the patient; analyzing the health related data with the controller; determining in the controller from the analyzing of the health related data, an OSA risk factor having a correlation to OSA severity in the patient; and providing the OSA risk factor to the patient. US 20220016371 Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARTIN NATHAN ORTEGA whose telephone number is (571)270-7801. The examiner can normally be reached M-F 7:10 am - 5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert (Tse) Chen can be reached at (571) 272-3672. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARTIN NATHAN ORTEGA/Examiner, Art Unit 3791 /TSE CHEN/Supervisory Patent Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 3 earlier events
Feb 18, 2026
Applicant Interview (Telephonic)
Feb 18, 2026
Examiner Interview Summary
Feb 20, 2026
Response Filed
Jun 12, 2026
Final Rejection mailed — §103
Aug 12, 2026
Response after Non-Final Action
Sep 11, 2026
Request for Continued Examination
Sep 15, 2026
Response after Non-Final Action
Oct 01, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12765868
DEVICE AND METHOD FOR THE TREATMENT OF CANCEROUS LESIONS AND THE LIKE
5y 9m to grant Granted Oct 20, 2026
Patent 12765812
SYSTEMS AND METHODS FOR NONINVASIVE MONITORING OF THE BODY FLUID STATUS AND HEMOGLOBIN, AND USING THE SAME FOR AN AUTOMATED DECISION SUPPORT
1y 5m to grant Granted Oct 20, 2026
Patent 12727865
MEDICAL DEVICE FOR CONDUCTING PAPANICOLAOU (PAP) TEST
5y 7m to grant Granted Sep 08, 2026
Patent 12702266
MEDICAL CONTROL DEVICE AND MEDICAL OBSERVATION SYSTEM
5y 7m to grant Granted Aug 11, 2026
Patent 12690818
EVENT-ORIENTED PREDICTIONS OF GLYCEMIC RESPONSES
4y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
27%
Grant Probability
60%
With Interview (+32.8%)
3y 11m (~9m remaining)
Median Time to Grant
High
PTA Risk
Based on 82 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month